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Abstract
In systemic sclerosis (SSc), dermal capillaries are progressively lost with consequent
chronic tissue hypoxia insufficiently compensated by angiogenesis. Clinical studies re-
ported that intravenous cyclophosphamide (CYC) may improve SSc-related peripheral mi-
crovascular damage. Recently, we showed that CYC treatment may normalize SSc sera-
induced abnormalities in endothelial cell-matrix interactions. Our objective was to evaluate
in vitro the effects of sera from treatment-naïve or CYC-treated SSc patients on dermal
blood microvascular endothelial cell (dMVEC) angiogenesis, migration, proliferation and ap-
optosis. dMVECs were challenged with sera from 21 SSc patients, treatment-naïve (n = 8)
or under CYC treatment (n = 13), and 8 healthy controls. Capillary morphogenesis on Gel-
trex matrix was significantly reduced upon challenge with sera from naïve SSc patients
compared with healthy controls. When dMVECs were challenged with sera from CYC-treat-
ed SSc patients, their angiogenic capacity was comparable to that of cells treated with
healthy sera. Wound healing capacity and chemotaxis in Boyden chamber were both signifi-
cantly decreased in the presence either of naïve or CYC-treated SSc sera compared with
healthy sera. WST-1 assay revealed that cell proliferation was significantly decreased in
dMVECs challenged with sera from naïve SSc patients compared with healthy sera. Con-
versely, dMVEC proliferation was not impaired in the presence of sera from CYC-treated
SSc patients. Accordingly, the percentage of TUNEL-positive apoptotic dMVECs was sig-
nificantly higher in the presence of sera from naïve SSc patients than healthy controls, while
CYC-treated SSc sera did not induce dMVEC apoptosis. Levels of the angiostatic mediators
endostatin, pentraxin 3, angiostatin and matrix metalloproteinase-12 were all significantly
elevated in sera from naïve SSc patients compared with sera from both healthy controls
and CYC-treated SSc patients. In SSc, CYC treatment might boost angiogenesis and
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consequently improve peripheral microangiopathy through the normalization of the endo-
thelial cell-matrix interactions, reduction of endothelial cell apoptosis and rebalance of dys-
regulated angiostatic factors.
Introduction
Systemic sclerosis (SSc) is a chronic connective tissue disease characterized by microvascu-
lar abnormalities, production of autoantibodies and progressive fibrosis of the skin and
internal organs [1,2]. Two different subsets of SSc are commonly recognized: limited cuta-
neous SSc (lSSc) and diffuse cutaneous SSc (dSSc), which differ in the extent of dermal fi-
brosis, internal organ involvement, autoantibodies, prognosis and survival [1–3]. In both
forms the first symptom, that may precede of several years the onset of fibrosis, is Raynaud’s
phenomenon, a reversible vasospasm of hands and feet which may lead in time to digital ul-
cers and even gangrene of the extremities with a major impact on patients’ quality of life
[4,5]. In SSc, nailfold videocapillaroscopy highlights several microvascular abnormalities
which culminate in the loss of peripheral capillary vessels leading to chronic tissue ischemia
[5–7].
Tissue ischemia and hypoxia are usually the main triggers for angiogenesis through the
upregulation of proangiogenic factors, which overcome angiostatic factors and initiate angio-
genic sprouting from pre-existing microvessels by inducing vasodilation and activation of mi-
crovascular endothelial cells (MVECs) [8,9]. During angiogenesis, activated MVECs lose
connections with each other, release proteolytic enzymes that degrade the basement mem-
brane, migrate into the surrounding extracellular matrix, proliferate and assemble in capillary
tubes. A vascular lumen is then formed and the vessel wall is eventually stabilized by the re-
cruitment of supporting cells as pericytes and smooth muscle cells [8,9].
Despite chronic MVEC activation/damage and progressive reduction in peripheral
capillary density, in SSc vascular recovery appears to be precluded by a dysregulated and in-
sufficient angiogenic process [5,10–12]. An imbalanced expression of a wide array of circu-
lating proangiogenic and angiostatic factors may be largely responsible for this complex
scenario [5,10–16]. Moreover, an impaired response to proangiogenic stimuli and several
functional defects have been reported in skin MVECs and peripheral blood-derived endo-
thelial progenitor cells from SSc patients [10–12,17–26]. However, the question why the
damaged microvessels in SSc are insufficiently replaced by new ones via angiogenesis or
vasculogenesis is still unresolved. As a consequence, currently there still are few therapeutic
options to promote effective angiogenesis and regeneration of the peripheral microcircula-
tion [27–31].
In the present study, we evaluated whether sera from lSSc and dSSc patients may affect the
angiogenic performance of human adult dermal blood MVECs (dMVECs). For this purpose,
we tested the capacity of dMVECs to i) align and form capillary-like tubes in vitro, ii) migrate
and proliferate in response to mechanical injury, and iii) migrate in response to a chemotactic
stimulus. Moreover, we specifically assessed whether lSSc and dSSc sera may impair prolifera-
tion and induce apoptosis of dMVECs. Since in SSc previous studies have shown that cyclo-
phosphamide (CYC) treatment may clinically improve microvascular damage, as assessed by
nailfold videocapillaroscopy [32], and normalize aberrant endothelial cell-matrix interactions
in vitro [33], the possible effect of sera from SSc patients treated with CYC on the angiogenic
capacity, proliferation and apoptosis of dMVECs was also investigated.
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Materials and Methods
Patients and serum samples
Serum samples were obtained from a total of 21 consecutive patients (17 women, 4 men) classi-
fied as SSc [34] and recruited from the Division of Rheumatology, University of Florence, Flor-
ence, Italy. Patients with symptoms overlapping with those of other autoimmune, rheumatic
and/or connective tissue diseases were excluded from the study. Eight age-matched and sex-
matched healthy individuals were used as controls. Patients were further classified in the limit-
ed SSc (lSSc; n = 13) or diffuse SSc (dSSc; n = 8) subsets [35]. All SSc patients were clinically as-
sessed as previously described [15,33]. Thirteen patients (8 lSSc and 5 dSSc) were receiving
monthly intravenous infusion of CYC (dose range, 1 to 1.5 g/m2 for 12 to 18 months), and the
other eight patients were not taking any immunosuppressant or disease-modifying drugs.
Blood was drawn from CYC-treated patients 1 month after the last infusion. Before blood sam-
pling, all patients were washed out for 10 days from oral vasodilating drugs and for 2 months
from intravenous prostanoids. Fresh venous blood samples from patients and healthy controls
were allowed to clot for 30 minutes before centrifugation at 1,500 g for 15 minutes. Serum was
collected and stored in aliquots at –80°C until used. All SSc patients and control subjects signed
an informed consent form, and the study was conducted in compliance with the principles of
the Declaration of Helsinki and was approved by the local institutional review board at the
Azienda Ospedaliero-Universitaria Careggi (AOUC), Florence, Italy.
Cells
Human adult dMVECs were obtained from Lonza (HMVEC-dBlAd; Lonza, Milan, Italy).
These cells are90% pure, express CD31, CD105, vonWillebrand factor and demonstrate
acetylated low density lipoprotein uptake according to the manufacturer’s certificate. Three cell
lines from different donors were used in the experiments. dMVECs were cultured according to
the manufacturer’s instructions in complete Endothelial Growth Medium 2 (EGM-2) supple-
mented with the EGM-2-MV BulletKit (Lonza) until confluent. Once at confluence, cells were
trypsinized with a trypsin/ethylenediaminetetraacetic acid solution (Lonza), centrifuged, resus-
pended in medium with EGM-2-MV and seeded onto appropriate supports for the different
assays.
In vitro capillary morphogenesis assay on Geltrex
Geltrex reduced growth factor basement membrane matrix (Invitrogen, Carlsbad, California,
USA) was used for the in vitro capillary morphogenesis assays. Culture wells (BD Falcon
96-multiwells, well surface 0.32 cm2; BD Biosciences, San Diego, California, USA) were coated
with Geltrex (32 μl/well). Geltrex was allowed to polymerize 30 minutes at 37°C prior to seed-
ing cells at the density of 14 x 103 in 100 μl of endothelial basal medium (EBM) containing 2%
of fetal bovine serum (FBS) and 10% of serum from lSSc or dSSc patients, naïve or under phar-
macological therapy with CYC, or 10% of serum from healthy controls. Positive controls were
obtained using complete EGM-2-MVmedium, which contains vascular endothelial growth
factor (VEGF) and 5% of FBS, to verify the efficiency of the assay (i.e., the capability of cells to
form capillaries in vitro). Wells were photographed under a Nikon Eclipse T5100 inverted
phase contrast microscope (Nikon, Tokyo, Japan) with a x4 objective at 24 hours after cell
seeding in 4 predetermined spots/well. Branching points were independently counted by two
independent observers in a blinded manner. The total number of branching points in the 4
photographic fields of each plate was considered indicative of the complexity of the capillary
network formed. All experimental conditions were tested in duplicate.
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Wound healing assay
dMVECs were seeded into 12-multiwell plates at the density of 50 x 103 cells/well in complete
EGM-2-MV medium. Once at confluence, cells were starved in EBM with 2% FBS. After 2
hours, the medium was removed and the monolayer was scratched with a sterile 1000-μl pi-
pette tip. The resulting wound was ~ 1 mm wide. After careful washing with phosphate-buff-
ered saline (PBS), cells were fed with 1 ml of EBM containing 2% FBS and 10% of serum from
lSSc or dSSc patients, naïve or under pharmacological therapy with CYC, or 10% of serum
from healthy controls. Positive controls were obtained using complete EGM-2-MV medium to
verify the efficiency of the assay. All experimental conditions were tested in duplicate. The
wounded area was observed at 0, 6 and 24 hours after scratching. At 24 hours, a predetermined
field encompassing almost all the wounded area was photographed under a Nikon Eclipse
T5100 inverted microscope (Nikon) with a x10 objective. The percentage of repair was evaluat-
ed with the “Area fraction” function of the NIS-Elements software version 2.3 (Nikon).
In vitro chemotaxis assay
Chemotaxis was assessed by using the Boyden chamber assay performed in 24-multiwell plates
with inserts containing an 8-μm pore size polyethylene terephthalate (PET) membrane (BD
Biosciences). The solution to be tested (750 μl of EBM containing 2% of FBS and 10% of serum
from lSSc or dSSc patients, naïve or under pharmacological therapy with CYC, or 10% of
serum from healthy controls) was placed in the lower chamber. Positive controls were obtained
with complete EGM-2-MVmedium to verify the efficiency of the assay. A chemokinetic effect
was excluded using EBM in both the upper and the lower well. Under this condition we failed
to detect any cell on the lower side of the membrane. A suspension of 25 x 103 dMVECs/insert
in EBM containing 2% of FBS was added in the upper chamber. All experimental conditions
were tested in duplicate. At 24 hours after cell seeding the inserts with adhering cells were fixed
in situ for 2 minutes with 3% formalin in PBS and then permeabilized for 20 minutes with
methanol. Non-migrated cells were mechanically removed from the upper surface of the PET
membrane by scrubbing with a cotton-tipped swab. Membranes were then stained for 15 min-
utes with Giemsa Stain (J.T. Baker; VWR International, Milan, Italy), washed with PBS, de-
tached from the insert with a blade and mounted upside down on glass slides. Each membrane
was photographed under a Nikon E600 light microscope (Nikon) with a x20 objective in 4 ran-
domly selected fields. Migrated cells were counted in a blinded manner by two independent ob-
servers with the aid of the NIS-Elements software version 2.3 (Nikon).
Cell proliferation assay
dMVECs were seeded into 96-multiwell plates (40 x 103 cells/well) in complete EGM-2-MV
medium and were left to adhere overnight. Cells were then washed 3 times with serum-free me-
dium and incubated in EBM with 2% FBS for 24 hours. Subsequently, dMVECs were incubated
for 24 hours in EBM containing 2% FBS and 10% of serum from lSSc or dSSc patients, naïve or
under pharmacological therapy with CYC, or 10% of serum from healthy controls. The prolif-
erative effect with complete EGM-2-MV medium was defined as the optimal growth and was
set as 100% proliferation. Cell proliferation was determined by the Cell Proliferation Reagent
WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)
colorimetric assay (Roche Diagnostics, Mannheim, Germany) according to the manufacturer’s
instructions. All measurements were performed in triplicate.
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Detection of apoptosis by TUNEL assay
dMVECs were grown to confluence on glass coverslips, starved in EBM with 2% FBS overnight
and then incubated for 24 hours in EBM containing 2% FBS and 10% of serum from lSSc or
dSSc patients, naïve or under pharmacological therapy with CYC, or 10% of serum from
healthy controls. dMVECs were subsequently fixed in 3.7% buffered paraformaldehyde and
permeabilized with 0.1% Triton X-100 in PBS. For immunofluorescent detection and quantifi-
cation of cell apoptosis we used the terminal deoxynucleotidyl transferase-mediated dUTP
nick-end labeling (TUNEL) technology (Fluorescein Isothiocyanate (FITC) In Situ Cell Death
Detection Kit; Roche Diagnostics) according to the manufacturer’s instructions. Nuclei were
counterstained with 4’,6-diamidino-2-phenylindole (DAPI). The stained cells were observed
under a Leica DM4000 B microscope (Leica Microsystems, Mannheim, Germany) and photo-
graphed using a Leica DFC310 FX 1.4-megapixel digital colour camera equipped with the Leica
software application suite LAS V3.8 (Leica Microsystems). The percentage of apoptotic
dMVEC nuclei was calculated as TUNEL/DAPI-positive nuclei in proportion to all DAPI-posi-
tive nuclei. Counting was performed on ten randomly chosen microscopic fields (x40 original
magnification) per sample by two independent blinded observers.
Enzyme-linked immunosorbent assay
Levels of the angiostatic mediators endostatin, pentraxin 3 (PTX3), angiostatin and matrix
metalloproteinase-12 (MMP-12) in serum samples were measured by commercial quantitative
colorimetric sandwich enzyme-linked immunosorbent assay (Human Endostatin Quantikine
ELISA Kit and Human Pentraxin 3/TSG-14 Quantikine ELISA Kit, R&D Systems, Minneapo-
lis, Minnesota, USA; Human Angiostatin ELISA Kit, RayBiotech, Norcross, Georgia, USA;
Human Matrix Metallopeptidase 12 ELISA Kit, Antibodies-online, Atlanta, Georgia, USA) ac-
cording to the manufacturer’s protocol. The detection range was 0.31–10 ng/ml for endostatin,
0.31–20 ng/ml for PTX3, 20–2000 ng/ml for angiostatin and 0.156–10 ng/ml for MMP-12.
Serum samples were diluted 1:4 for the endostatin assay. Concentrations were calculated using
a standard curve generated with specific standards provided by the manufacturer. Each sample
was measured in duplicate.
Statistical analysis
Data presented are means and standard errors of the mean (SEM). Statistical analysis was per-
formed using the Student’s t-test for independent groups. A p-value less than 0.05 according to
a two-tailed distribution was considered statistically significant.
Results
Demographic and clinical data of SSc patients
The demographic, clinical and serological characteristics of the SSc patients enrolled in the
study are listed in Table 1. As reported in Table 1, CYC was given for 12–18 months to thirteen
patients (three males and ten females), in eight cases for interstitial lung disease and in the re-
maining five cases for severe and rapidly progressive cutaneous involvement during the early
phase of the disease; six of them were anti-Scl70 positive.
Effects of SSc sera on in vitro capillary morphogenesis
dMVECs formed capillary-like tubes in all experimental conditions assayed (Fig 1A). At 3
hours after seeding on Geltrex, cells had already aligned and formed linear capillary-like
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structures. After 6–8 hours, new branches sprouted from the pre-existing ones, and at 24 hours
a network of closed capillary-like structures provided with a lumen had formed (Fig 1A).
The number of branching points was significantly lower upon challenge of dMVECs with
sera from treatment-naïve SSc patients compared with healthy controls (p<0.005) (Fig 1B). In
particular, although to a different extent, differences between either naïve lSSc or naïve dSSc
sera and healthy control sera were statistically significant (p<0.05 and p<0.005, respectively)
(Fig 1B). Moreover, the angiogenic response was significantly lower in the presence of naïve
dSSc sera compared with naïve lSSc sera (p = 0.02) (Fig 1B). When dMVECs were challenged
with sera from CYC-treated lSSc and dSSc patients, their angiogenic response was comparable
to that of cells treated with healthy sera (Fig 1B). Accordingly, either when considering the
whole SSc group or the lSSc and dSSc subsets separately, the angiogenic performance of
dMVECs was significantly greater upon challenge with sera from CYC-treated patients com-
pared with naïve patients (p<0.005 for all comparisons).
Effects of SSc sera on wound healing capacity of dMVECs
After scratching in the presence of healthy control sera, dMVECs migrated into the wounded
area and then proliferated, and at 24 hours the monolayer integrity was completely restored
(Fig 2A). Conversely, at 24 hours after scratching in the presence of sera from both lSSc and
dSSc patients, dMVECs were unable to restore the monolayer integrity (Fig 2A). Indeed,
wound healing capacity was significantly decreased upon challenge of dMVECs with sera from
both treatment-naïve and CYC-treated SSc patients compared with healthy controls (both
p<0.005), without any significant difference between naïve and CYC-treated SSc sera (Fig 2B).
Table 1. Demographic and clinical characteristics of patients with SSc.
Age, mean ± SD (years) 56.5 ± 12.1
Male 4 (19.1%)
Female 17 (80.9%)
lSSc subset 13 (61.9%)
dSSc subset 8 (38.1%)




Digital ulcers 12 (57.1%)
Early NVC pattern 4 (19.1%)
Active NVC pattern 8 (38.1%)
Late NVC pattern 9 (42.9%)
Skin score, mean ± SD 10.2 ± 6.3
ILD# 11 (52.4%)
CYC treatment 13 (61.9%)¥
ACA, anticentromere antibodies; ANA, antinuclear antibodies; Anti-Scl70, anti-Scl70 antibodies; CYC,
cyclophosphamide; dSSc, diffuse cutaneous systemic sclerosis; ILD, interstitial lung disease; lSSc, limited
cutaneous systemic sclerosis; NVC, nailfold videocapillaroscopy; SSc, systemic sclerosis.
Except where indicated otherwise, values are the absolute number and percentage of patients.
§Disease duration was calculated since the first non-Raynaud’s symptom of SSc.
#Determined by high-resolution computed tomography scan.
¥Eight patients with lSSc and five patients with dSSc.
doi:10.1371/journal.pone.0130166.t001
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Fig 1. Systemic sclerosis (SSc) sera impair the ability of dermal microvascular endothelial cells
(dMVECs) to form capillary-like tubes on Geltrex matrix. In vitro capillary morphogenesis of dMVECs was
evaluated after challenge with sera from healthy controls (CTR, n = 8) and SSc patients, treatment-naïve
(n = 8) or under cyclophosphamide (CYC) treatment (n = 13). (A) Representative images of the capillary
network formed on Geltrex at 24 hours from plating are shown for each experimental point. Original
magnification, ×4. The square panels at the bottom provide higher magnification views of the encircled areas
in CTR panel to demonstrate the presence of capillary-like structures provided with a lumen. (B)Quantitative
Cyclophosphamide Counteracts Antiangiogenic Effects of SSc Sera
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Furthermore, wound healing capacity was significantly lower when dMVECs were challenged
with naïve dSSc sera compared with naïve lSSc sera (p<0.001) (Fig 2B).
analysis of the number of branching points as a measure of the complexity of the capillary network formed.
Data are means ± SEM of three independent experiments performed in duplicate with each one of the three
dMVEC lines. *p<0.05 and **p<0.005 vs. healthy controls, §p = 0.02 vs. naïve lSSc. dSSc, diffuse cutaneous
SSc; lSSc, limited cutaneous SSc.
doi:10.1371/journal.pone.0130166.g001
Fig 2. Systemic sclerosis (SSc) sera impair wound healing capacity of dermal microvascular endothelial cells (dMVECs).Wound healing capacity of
dMVECs was assayed in the presence of sera from healthy controls (CTR, n = 8) and SSc patients, treatment-naïve (n = 8) or under cyclophosphamide
(CYC) treatment (n = 13). (A) Representative images of the wounded area at 0 hours and 24 hours after scratching. Original magnification, ×10. (B)
Quantitative analysis of the percentage of wound repair. Data are means ± SEM of three independent experiments performed in duplicate with each one of
the three dMVEC lines. **p<0.005 vs. healthy controls, §p<0.001 vs. naïve lSSc. dSSc, diffuse cutaneous SSc; lSSc, limited cutaneous SSc.
doi:10.1371/journal.pone.0130166.g002
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Effects of SSc sera on in vitro chemotaxis of dMVECs
The chemotaxis assay revealed a prominent inhibitory effect of sera from both lSSc and dSSc
patients on dMVEC migration (Fig 3A). Indeed, dMVECs challenged with either treatment-
naïve SSc or CYC-treated SSc sera displayed significantly lower chemotactic capacity compared
with cells challenged with healthy sera (both p<0.001), with no significant difference between
Fig 3. Systemic sclerosis (SSc) sera impair chemotaxis of dermal microvascular endothelial cells
(dMVECs). Chemotaxis of dMVECs was assessed by using the Boyden chamber assay, placing in the lower
compartment sera from healthy controls (CTR, n = 8) and SSc patients, treatment-naïve (n = 8) or under
cyclophosphamide (CYC) treatment (n = 13). (A) Representative images of the filters showing migrated cells
labeled with Giemsa Stain. Original magnification, ×4. (B)Quantitative analysis of chemotaxis expressed as
the number of migrated cells per filter. Data are means ± SEM of three independent experiments performed in
duplicate with each one of the three dMVEC lines. *p<0.05 and **p<0.001 vs. healthy controls, §p<0.001 vs.
naïve lSSc. dSSc, diffuse cutaneous SSc; lSSc, limited cutaneous SSc.
doi:10.1371/journal.pone.0130166.g003
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naïve and CYC-treated SSc sera (Fig 3B). Moreover, chemotaxis was significantly lower in the
presence of naïve dSSc sera compared with naïve lSSc sera (p<0.001) (Fig 3B).
Effects of SSc sera on dMVEC proliferation and apoptosis
Either when considering the whole SSc group or the lSSc and dSSc subsets separately, cell pro-
liferation was significantly decreased in dMVECs challenged with sera from naïve SSc patients
compared with healthy sera (p<0.01 for all comparisons) (Fig 4). Moreover, cell proliferation
was significantly lower in the presence of naïve dSSc sera compared with naïve lSSc sera
(p = 0.01) (Fig 4). Conversely, when dMVECs were challenged with sera from CYC-treated
lSSc and dSSc patients, cell proliferation was comparable to that of cells treated with healthy
sera (Fig 4).
dMVEC apoptosis in the different experimental conditions was assessed by fluorescent
TUNEL assay (Fig 5A). The percentage of apoptotic cells was significantly increased upon chal-
lenge of dMVECs with sera from naïve SSc patients compared with healthy controls (p<0.001)
(Fig 5B). In particular, differences between either naïve lSSc or naïve dSSc sera and healthy sera
were statistically significant (both p<0.001) (Fig 5B). Furthermore, apoptosis was greater in
the presence of naïve dSSc sera than naïve lSSc sera, but this difference did not reach statistical
significance (p = 0.07) (Fig 5B). Of note, no difference in apoptosis rate was observed between
dMVECs challenged with sera from CYC-treated SSc patients and those treated with healthy
sera (Fig 5B). Consistent with these findings, the percentage of apoptotic dMVECs was signifi-
cantly lower upon challenge with sera from CYC-treated patients compared with sera from
naïve patients (p<0.001).
Fig 4. Systemic sclerosis (SSc) sera impair proliferation of dermal microvascular endothelial cells (dMVECs). Cell proliferation was measured by the
WST-1 colorimetric assay after challenge for 24 hours with sera from healthy controls (CTR, n = 8) and SSc patients, treatment-naïve (n = 8) or under
cyclophosphamide (CYC) treatment (n = 13). Cell proliferation in the presence of complete EGM-2-MVmedium was set to 100%; all results are normalized to
this value. Data are means ± SEM of three independent experiments performed in duplicate with each one of the three dMVEC lines. **p<0.01 vs. healthy
controls. dSSc, diffuse cutaneous SSc; lSSc, limited cutaneous SSc.
doi:10.1371/journal.pone.0130166.g004
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Fig 5. Systemic sclerosis (SSc) sera induce apoptosis of dermal microvascular endothelial cells (dMVECs). Apoptosis was evaluated by fluorescent
TUNEL assay after challenge for 24 hours with sera from healthy controls (CTR, n = 8) and SSc patients, treatment-naïve (n = 8) or under cyclophosphamide
(CYC) treatment (n = 13). (A) Representative images of dMVECs subjected to FITC-TUNEL (green) labeling and DAPI (blue) counterstaining for nuclei.
Apoptotic nuclei are green/blue double stained. Original magnification, ×20. (B)Quantitative analysis of the percentage of apoptotic dMVECs. Data are
means ± SEM of three independent experiments performed in duplicate with each one of the three dMVEC lines. **p<0.001 vs. healthy controls. dSSc,
diffuse cutaneous SSc; lSSc, limited cutaneous SSc.
doi:10.1371/journal.pone.0130166.g005
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Levels of angiostatic factors in naïve and CYC-treated SSc sera
Serum levels of endostatin were significantly increased in naïve SSc patients (22.21 ± 2.80 ng/ml)
compared both with healthy controls (12.84 ± 2.52 ng/ml, p = 0.02) and CYC-treated SSc pa-
tients (13.95 ± 2.11 ng/ml, p = 0.03) (Fig 6A). As displayed in Fig 6B, levels of PTX3 in naïve
SSc sera (2.60 ± 0.43 ng/ml) were significantly higher than in control sera (1.09 ± 0.22 ng/ml,
p = 0.008) and CYC-treated SSc sera (1.17 ± 0.16 ng/ml, p = 0.002). Serum angiostatin was sig-
nificantly increased in naïve SSc patients (82.59 ± 10.57 ng/ml) compared to controls (52.19 ±
5.49 ng/ml, p = 0.02) (Fig 6C). Moreover, angiostatin was higher in naïve SSc than in CYC-
treated SSc sera (60.65 ± 6.82 ng/ml), although this difference was not statistically significant
(p = 0.08) (Fig 6C). A significant increase in serum levels of MMP-12 was detected in naïve SSc
patients (2.70 ± 0.46 ng/ml) compared with controls (1.28 ± 0.36 ng/ml, p = 0.03) and CYC-treat-
ed SSc patients (1.34 ± 0.27 ng/ml, p = 0.01) (Fig 6D). No difference in serum levels of endostatin,
PTX3, angiostatin and MMP-12 was found between healthy controls and CYC-treated SSc pa-
tients (Fig 6A–6D).
Fig 6. Serum levels of negative angiogenesis regulators. Levels of endostatin (A), pentraxin 3 (PTX3) (B), angiostatin (C) and matrix metalloproteinase-
12 (MMP-12) (D) were measured by quantitative colorimetric sandwich ELISA in sera from healthy controls (CTR, n = 8) and SSc patients, treatment-naïve
(n = 8) or under cyclophosphamide (CYC) treatment (n = 13). Data are means ± SEM. p-values are indicated in each panel.
doi:10.1371/journal.pone.0130166.g006
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Discussion
Our study demonstrates that i) in vitro angiogenesis and survival of dMVECs are significantly
and differentially impaired by sera from lSSc and dSSc patients, these latter displaying the
strongest inhibitory effect, and ii) treatment with the powerful immunosuppressant CYC may
effectively abolish such antiangiogenic and proapoptotic actions, possibly explaining the CYC-
mediated improvement of SSc peripheral microangiopathy observed in clinical practice [32].
The different in vitro assays used in this work exploit different endothelial cell processes re-
quired during angiogenesis. The capillary tube assay on Geltrex allows to evaluate the ability of
MVECs to organize in a physiologic extracellular matrix. Geltrex is in fact a soluble form of re-
duced growth factor basement membrane extract purified from murine Engelbreth-Holm-
Swarm tumor and, like Matrigel, is rich in laminin, collagen IV, entactin, and heparan sulfate
proteoglycan. Upon seeding on Geltrex, MVECs rapidly form capillary-like tubes. Since during
in vitro angiogenesis endothelial cells first align and then sprout from the neoformed capillary
vessels to form a network, we quantitatively assayed the angiogenic process by counting the
number of branching points as a direct measure of the complexity of the mesh formed.
To recapitulate in vitro a physiologic or pathologic bloodstream environment, we exposed
dMVECs to sera from healthy controls or SSc patients, which were treatment-naïve or under
CYC treatment. In the presence of sera from both naïve lSSc and dSSc patients, the number of
branching points formed by dMVECs was significantly lower compared to cells challenged
with healthy sera. These findings are in agreement with a previous work demonstrating antian-
giogenic plasma activity in patients with SSc, which was mainly attributed to the increased lev-
els of antiangiogenic angiostatin [36]. Moreover, here we report for the first time that the
antiangiogenic activity of dSSc sera is significantly greater than that of lSSc sera, which is con-
sistent with the higher prevalence of most severe peripheral vascular manifestations reported
in the dSSc subset, such as avascular areas on nailfold videocapillaroscopy and digital ulcers
[37–39]. This reduced capacity to form capillary-like tubes in vitro is likely to be imputed to
the profound imbalance between proangiogenic and angiostatic factors described in the SSc
bloodstream [5,10–16,40,41]. Indeed, we herein show that our naïve SSc sera contain increased
levels of different negative angiogenesis regulators, including endostatin, angiostatin, PTX3
and MMP-12. Endostatin and angiostatin are considered among the most powerful angiogene-
sis inhibitors [10,36]. PTX3 is a multifunctional pattern recognition protein that can suppress
the proangiogenic action of fibroblast growth factor 2 (FGF2) and has been associated with SSc
vascular manifestations and defective angiogenesis [20,42]. In SSc, elevated levels of MMP-12
may suppress angiogenesis through the cleavage and subsequent inactivation of endothelial
urokinase-type plasminogen activator receptor, as well as through the proteolysis of plasmino-
gen and generation of angiostatin [15,19,20]. In addition, SSc serum has been reported to con-
tain anti-endothelial cell antibodies that may induce endothelial cell apoptosis [43–45] and
anti-fibrillin-1 antibodies that may alter the interaction of endothelial cells with the surround-
ing extracellular matrix [46,47]. In agreement with these findings, we also observed an in-
creased apoptosis rate in dMVECs upon incubation with naïve SSc sera.
Of note, such antiangiogenic and proapoptotic effects were observed by using sera from
both lSSc and dSSc patients who were not under treatment with immunosuppressant or dis-
ease-modifying drugs. Conversely, the addition of sera from CYC-treated SSc patients did not
impair the angiogenic ability of dMVECs, as shown by a number of branching points compara-
ble to that of cells challenged with healthy sera. Thus, CYC treatment seems to be able to block
the antiangiogenic activity of SSc sera. CYC is a potent immunosuppressant used in the treat-
ment of different autoimmune diseases such as systemic lupus erythematosus, vasculitis, myo-
sitis and also SSc, especially in patients with interstitial lung disease [48,49]. As the last CYC
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infusion has been administered to our patients 1 month before blood withdrawal, this benefi-
cial action on angiogenesis is unlikely to be a direct effect of the drug. CYC treatment might
rather have rebalanced circulating levels of positive and negative regulators of angiogenesis,
possibly via its immunosuppressive action. Indeed, CYC exerts its anti-inflammatory and im-
munosuppressive functions through direct cytotoxicity on bone marrow precursors and ma-
ture immune cells, mainly B and T cells [50]. During angiogenesis, cells of both the innate and
adaptive immune systems are involved in the mechanisms of endothelial cell activation, prolif-
eration and migration through the production and release of a large spectrum of angiogenic
mediators [51]. In this regard, in vitro studies on peripheral blood mononuclear cells suggested
a defective contribution of SSc lymphocytes and monocytes to angiogenesis [52,53]. Further-
more, supernatants from SSc peripheral blood mononuclear cells decreased endothelial cell
chemotaxis [54], and SSc serum failed to enhance normal mononuclear cell angiogenic capaci-
ty [55]. Therefore, our findings might be explained by the possible CYC-mediated modulation
of immune cell-derived proangiogenic and antiangiogenic molecules. To explore this hypothe-
sis, we looked at possible differences in serum levels of some antiangiogenic factors that have
been implicated in SSc [10,15,19,20,36,42]. Strikingly, we observed significantly reduced levels
of endostatin, angiostatin, PTX3 and MMP-12 in CYC-treated SSc sera compared with naïve
SSc sera. Indeed, circulating levels of the aforementioned molecules in CYC-treated SSc pa-
tients were comparable to healthy controls. In addition, CYC treatment might have reduced
serum levels of autoantibodies acting on the endothelium, including proapoptotic anti-endo-
thelial cell antibodies and anti-fibrillin-1 antibodies, via depletion of autoreactive B lympho-
cytes. In this regard, we found that the percentage of TUNEL-positive apoptotic dMVECs was
significantly higher in the presence of sera from naïve SSc patients compared with healthy con-
trols, while CYC-treated SSc sera did not induce dMVEC apoptosis. However, at this stage we
did not investigate possible differences in the presence of such autoantibodies between naïve
and CYC-treated SSc sera.
In an experimental setting quite similar to the present one, we have previously shown that
stimulation of dMVECs with CYC-treated SSc sera preserved their ability to synthesize fibril-
lin-1 and the expression of the adhesion molecule αvβ3 integrin, which instead were both im-
paired on challenge with naïve SSc sera [33]. Of note, αvβ3 integrin is a crucial angiogenesis
regulator [56] and fibrillin-1 has been reported to induce αvβ3 integrin-mediated signaling in
human endothelial cells [57]. Thus, CYC treatment might exert a proangiogenic effect by
maintaining endothelial αvβ3 integrin expression and fibrillin-1 deposition at normal levels.
Nevertheless, further in-depth studies will help to provide a mechanistic explanation for the
differential serum effects reported herein. In addition to its possible impact on fully differenti-
ated endothelial cell functions, it is noteworthy that in SSc patients CYC treatment may even
promote the mobilization of bone marrow-derived endothelial progenitor cells involved in vas-
culogenesis [58].
In accordance with the reduced angiogenesis observed on Geltrex, both dMVEC chemotaxis
and wound healing capacity were also greatly reduced in all the cultures challenged with naïve
SSc sera, with the strongest inhibitory effects being observed in the presence of dSSc sera. The
Boyden chamber assay exploits the capacity of cells to migrate in response to a chemoattractant
placed in the lower chamber, in our case SSc or healthy serum. The reduced cell migration ob-
served in the presence of sera from naïve SSc patients may suggest the action of some chemo-
taxis inhibitors. As an example, endostatin, which is increased in the serum of SSc patients
[10,40,59], has been shown to inhibit VEGF-induced human umbilical vein endothelial cell mi-
gration [60]. Other factors or autoantibodies present in SSc bloodstream might interfere with
the main promoters of endothelial cell migration, including FGF2, angiopoietins and platelet-
derived growth factor [61]. At variance with the Boyden chamber assay, the wound healing
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assay does not require only migration of cells but also proliferation, which may have been im-
paired by transforming growth factor-β (TGF-β) or other cytotoxic factors present in the
serum of SSc patients. Indeed, TGF-β has been shown to inhibit cell proliferation and induce
apoptosis of endothelial cells with a variety of mechanisms [62–64]. Interestingly, unlike what
we observed in the in vitro capillary morphogenesis assay, we could not find any significant dif-
ference between the effects of naïve and CYC-treated SSc sera either on dMVEC chemotaxis or
wound healing capacity. Of note, we further specifically assessed the effects of SSc sera on en-
dothelial cell proliferation using the WST-1 assay. Our findings revealed that cell proliferation
was significantly decreased in dMVECs challenged with sera from naïve SSc patients compared
with healthy sera. Conversely, dMVEC proliferation was preserved in the presence of sera from
CYC-treated SSc patients. Thus, the lack of wound healing capacity observed in the presence of
CYC-treated SSc sera is likely to be attributed to a selective impairment of dMVEC migration.
Taken together, CYC treatment seems unable to specifically counteract the anti-migratory ef-
fects of SSc sera. However, we should also consider that because of the lack of a matrix sub-
strate, chemotaxis and wound healing assays do not adequately reflect in vitro what is
happening in vivo. Instead, as assessed by capillary morphogenesis on Geltrex matrix, it is note-
worthy that even in the presence of CYC-treated SSc sera dMVECs could sustain a normal an-
giogenic program in a microenvironment which better reflects the in vivo situation. This might
be related to a rebalance of abnormalities in endothelial cell-matrix interactions following CYC
treatment, as suggested by our previous work [33].
Conclusions
In summary, our data clearly show that sera from naïve SSc patients significantly impair in
vitro capillary morphogenesis, wound healing capacity, chemotaxis and survival of dMVECs.
Among the endothelial cell functions investigated herein, cell proliferation and the ability to or-
ganize in capillary-like tubes were maintained at normal levels following CYC treatment. In
SSc, CYC treatment might boost angiogenesis and consequently improve peripheral microan-
giopathy mainly through the normalization of the endothelial cell-matrix interactions, reduc-
tion of endothelial cell apoptosis and rebalance of dysregulated angiostatic factors.
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